Preparation and use of novel MAO-b inhibitor containing tetralin-1-amine structure
By synthesizing compounds containing tetrahydronaphth-1-amine structures, the selectivity and safety issues of existing MAO-B inhibitors were resolved, achieving highly selective inhibition of MAO-B, improving Parkinson's disease symptoms and reducing the generation of oxygen free radicals.
Patent Information
- Application Number
- PCT/CN2025/121628
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-08
- Filing Date
- 2025-09-16
- Publication Date
- 2026-04-16
AI Technical Summary
Existing MAO-B inhibitors are non-selective and irreversible, leading to serious adverse reactions such as orthostatic hypotension, hypertensive crisis, caseous reaction, and liver toxicity, and cannot effectively relieve Parkinson's disease symptoms.
To develop a compound containing a tetrahydronaphth-1-amine structure, and to synthesize a highly selective MAO-B inhibitor via coupling, reduction and amino substitution reactions, and to prepare it in pharmaceutically acceptable forms such as hydrochloride.
It achieves highly selective inhibition of MAO-B, reduces the generation of peroxides in dopamine oxidation metabolism, reduces the production of oxygen free radicals, prevents dopamine degradation, improves Parkinson's disease symptoms, and delays the death of substantia nigra cells.